China Biotech Services Holdings Limited
Stock Code:8037.HK

China Biotech Services Holdings Limited
中國生物科技服務控股有限公司

A constituent stock of MSCI Hong Kong Micro Cap Index

Disclaimer

Forward-Looking Statement

This presentation may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, and our ability to protect our clients' intellectual property. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section.

Use of Adjusted Financial Measures (Non-IFRS Measures)

We have provided adjusted net profit, which excludes the share-based compensation expenses are not required by, or presented in accordance with, IFRS. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing underlying business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual and non-recurring items that we do not consider indicative of the performance of our business. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.

Highlights

BNCT

CAR-T

Precision Diagnostics

Corporate

Outlook

中國生物科技服務

Our Vision

Committed to building an advanced biotech platform that integrates cancer diagnosis and treatment.

The outline of “Healthy China 2030” indicates that the 5-year survival rate of cancer in China needs to be increased by 15% in 2030

The United States’ “Cancer Moonshot” Program: committed to reduce the cancer mortality rate by 50% over the next 25 years.



Highlights

中國生物科技服務

Diagnosis Hong Kong

Since 1968

- Long history;
- Largest scale;
- Latest technology.

BNCT Hainan

Globally Unique

- Approved BNCT equipment for marketing,
- Incorporated into Japan's national health insurance;
- Technological advantages: equipment miniaturization + low time cost + low maintenance cost;
- Known as the "crown pearl" in the field of radiotherapy;
- Will be the second country in the world to offer BNCT for patients upon completion of construction.

CAR-T Shanghai

IND CD20

- The first and only domestically declared and approved for IND CD20 targeted CAR-T in China;
- Has two international patents for CAR-T platform technology;
- Internationally renowned team of scientists.

Group Structure

中國生物科技服務控股
China Biotech Services

Precision Diagnostics

Sunrise Diagnostic Centre Limited 華昇診斷中心

One of the largest COVID-19 testing centres in Hong KOng
60%*

Asia Molecular Diagnostics Laboratory Limited 亞洲分子診斷實驗室有限公司

Harvard-led gene testing technology
77.6%

標準病理檢驗所有限公司
PHC Medical Diagnostic Centre Ltd.
Pathology & HealthCare

A Hong Kong testing brand with a history of over 50 years
97%

iCare

A one-stop health management centre
97%

Cancer Treatment

Boron Neutron Capture Therapy 鵬博医疗

BNCT

100%

LONGYAO 隆耀生物

Independent and Innovative Immunotherapy Technology

69%

*China Biotech Services Holdings Limited and a concerted party holds 40% and 20% equity interest in Sunrise Diagnostic Centre Limited, respectively. Therefore, China Biotech Services Holdings Limited is deemed to have a controlling interest of 60% in Sunrise Diagnostic Centre Limited.

Management Team： Professional Background, International Perspective

中國生物科技服務

Board Members

Liu Xiaolin
Chairman

- Vice Chairman of the Board at Nanjing Medical University
- Executive Director at Sunrise Diagnostic Centre Limited

Chui Hoi Yam
Executive Director

- Ex-president of Harbin Pharmaceutical Group Co., Ltd
- Ex- President of Novartis China
- Ex-Managing Director of SDICFUND
- Ex-Operations Director of China Merchant Group's Health Industry Division
- Ex-General Manager of China Merchant Group's Health Industry Investment Company

He Xun
Executive Director

- Bachelor in Chemical Engineering & Master in Biochemistry, Tsinghua University
- EMBA at National University of Singapore
- Founding chairman of Shenzhen Life Science and Biotechnology Association
- General manager of Guangdong Innovation Center for Small Molecule Drug Discovery

Dr. Huang Song
Executive Director

- Deputy Director of National Institute of Biological Sciences (NIBS), Beijing
- Director of Synthetic Biology, NIBS
- PhD in Biochemistry from University of Texas
- Bachelor of Biology from Peking University

Executive Team

Wayne Chen
CFO

- He has served as Chief financial Officer of Aseng Pharmaceutical, Deputy Chief Financial Officer and IR of Shanghai Fosun Pharmaceutical, Deputy General Manager and Financial Director of Shenzhen BGI, Business Director of Investment Banking Department of Citibank Securities in the East, and senior auditor of Ernst & Young
- Global Chartered Management Accountant and Senior Member of the Royal Institute of Chartered Management Accountants
- He holds a Bachelor's degree in food Science and Engineering from Shanghai Jiao Tong University
- China Europe Business School MBA

Edison Bina
CIO

- In charge of alternative investment business of CCB International Asset Management Company, industry group of Haitong International Investment Banking Department, and Singapore Dahua Securities, he has worked for many years
- He has participated in the listing and acquisition of a number of groups
- Bachelor of Economics and Political Science, University of London, MBA, Guanghua School of Management, Peking University

Prof. Yang Xuanming
Chief Scientist

- Special Researcher, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University
- Chief Scientist of Shanghai Longyao Biotech
- Post Doc in pathology, University of Chicago
- PhD at Center for Infection and Immunity, Chinese Academy of Sciences

Dr. Rubie Lo
Executive President
(New Drugs)

- Internationally certified for pharmaceutical and medical device regulatory affairs
- Master's degree in Pharmacy and Doctorate in Medical and Health Sciences
- Over 11 years of experience in large pharmaceutical groups in Hong Kong and completed over 700 registration projects. Specialized in the field of pharmaceuticals and medical devices.

Science & Technology Advisory Committee: Professional Background, International Perspective

中國生物科技服務

Prof. Yangxin Fu
Chief Scientific Advisor

- Current Chair Professor of Oncology, Tsinghua University School of Medicine
- Professor of Pathology & Chief Physician at UT Southwestern Medical Center
- Articles published on *Science*, *Nature* etc., cited over 30,000 times and had induced the discoveries of several clinical concept-directed drugs

Prof. Paul Waring
Chairman of Committee

- World renowned molecular pathologist
- Former Chairman of Pathology at Melbourne University
- Former Senior Director of Pathology and Diagnostics & vice President of Medical Innovation at Roche Diagnostics, USA
- Former Pathology Director at Peter MacCallum Cancer Centre, Melbourne

Dr. Shengli Bi
Project Leader of Vaccine Development

- Scientific Advisor of CBSH
- Researcher at Chinese Centre for Disease Control and Prevention, expert in coronavirus and hepatitis research
- Took part in the development of SARS vaccine in 2003
- Postdoc at US CDC and PhD at Chinese Academcy of Preventive Medicine

Prof. Gang Song
Senior Scientific Advisor

- Founder and Chairman of Board of Pillar Biosciences, USA
- Postdoc at Harvard Medical School
- PhD from Shanghai Medical College of Fudan University, China

Senior Consultants

Mr. Anthony Wu
Chief Consultant

- Standing member of Chinese People's Political Consultative Conference
- Served as the Chairman of the Hong Kong Hospital Authority for 10 years
- Member of the Deepening Medical Reform Expert Group of State Council
- Public Policy Expert of the National Health & Family Planning Commission
- Chief Advisor of National Administration of TCM

Eddy Lai
Chief Financial Officer

- Over 15 years' work experience in direct investment arm of Chinese conglomerate; completed a number of PE & strategic investment cases; focused on healthcare & wellness investments for more than 5 years
- Worked for major foreign investment bank and took part in IPOs, M&As and debt issuance
- MBA at University of Toronto, BBA at CUHK

Dr. Yao Shiego
Senior Consultant

- President of the Japan Branch of Shanghai University of Chinese Medicine
- Former Senior Scientist at P&G USA
- Former Project Leader at Otsuka Pharmaceutical
- Former director of Total Kenko Care, Tokyo
- PhD in molecular pathology at Kobe University, Japan

Highlights

BNCT

CAR-T

Precision Diagnostics

Corporate

Outlook

Boron Neutron Capture Therapy (BNCT)

Boron Neutron Capture Therapy
鹏博医疗

◆ BNCT

B——Boron, boron is the fifth chemical element

N——Neutron, a neutron is a part of the nucleus

C——Capture

T——Therapy





Boron Neutron capture therapy (BNCT), with its **biological targeting and heavy ion effect, can selectively and accurately "kill" tumor cells at the cell scale.**



Advantages of our BNCT technology (The fifth-generation advanced radiotherapy technology)

中國生物科技服務

1. In 2020, became the first boron neutron capture therapy in the world that has been approved for as a cancer treatment for routine clinical use.
2. Adopted neutron cyclotron equipment, **high safety**.
3. **Precise targeting of cells to kill cancer cells** with minimal damage to normal tissues.
4. The used boron compound has high tumor tissue uptake and long retention time; Low intake of normal tissues and quick clearance. No toxic or side effects.
5. **Compared with other particle therapy, the course of treatment is short, only one irradiation treatment is needed to kill tumor cells and tissues.**
6. Observing the process through multimodal images such as PETCT can evaluate and guide the formulation of treatment plan in advance.

Conditional characteristics		Photon line	Proton	Heavy ion	BNCT
Equivalent dose of attacking tumor cells	Type	photon (gamma ray, x ray, etc.)	Particle	Particle	Particle
			1H	12C	2He、3Li
	RBE/CBE	1	1.1	**3**	**3**
Treatment plan and cycle	Head and neck tumor	28 ~ 40 times	26 ~ 40 times	15 ~ 25 times	**1**
		6-8 weeks	5-8 weeks	3~5 weeks	
Beam control and patient position control		Required	Required	Required	Required
Treating tiny tumors		N/A	N/A	N/A	**Possible**
Dose to surrounding tissues and organs		High	Medium	Medium	**Low**

BNCT obtained approval for clinical use in Japan and included in national health insurance (Japan)

中國生物科技服務

◆ March 2020 -

Japan's BNCT equipment and boron medicine have obtained approval documents and are approved for marketing as a combination of medicine and equipment

製造販売承認を取得した２つの製品

【BNCT 治療システム NeuCure™（ニューキュア）】
医療機器製造販売承認番号　：30200BZX00084000　令和２年３月 11 日付

BNCT に使用することを目的とした中性子照射装置です。

【BNCT 線量計算プログラム NeuCure™ ドーズエンジン】
医療機器製造販売承認番号　：30200BZX00083000　令和２年３月 11 日付

日本標準商品分類番号
874291

承認番号	30200AMX00438000
販売開始	2020 年 5 月

ボロファラン（¹⁰B）

処方箋医薬品
注意−医師等の処方箋により使用すること

ステボロニン®点滴静注バッグ 9000 mg/300 mL
STEBORONINE® 9000 mg/300 mL for infusion

◆ June 2020 -

Japan's Ministry of Health, Labor and Welfare approves inclusion of BNCT in Japan's national health insurance

住友重機械工業　製品・ソリューション　技術情報　企業情報　株主・投資家の皆様へ　サステナビリティ

≡ お知らせ

2020年06月01日

住友重機械工業株式会社（社長：下村真司、以下　当社）は、加速器を用いたBNCT（ホウ素中性子捕捉療法）治療システムに関して、ステラファーマ株式会社（本社：大阪府大阪市、社長：浅野智之）と共同で頭頸部がんを対象とする臨床試験を実施しました。この結果を受けて、2019年10月11日に医療機器製造販売承認申請したBNCT治療システムNeuCure™、ならびにBNCT線量計算プログラムNeuCure™ドーズエンジンについて、2020年3月11日付けで、厚生労働省より新医療機器としての承認を取得し、6月1日付で保険収載されましたのでお知らせいたします。また、ステラファーマ株式会社のBNCT薬剤ステボロニン®が薬価収載され発売開始されました。これにより、当社の製品が世界で初めてBNCTを保険診療で利用することが可能になりました。BNCTが切除不能な局所進行または局所再発の頭頸部がんの新たな治療選択肢の一つとして、貢献できることを期待しています。

■保険適用の概要

一般名称	ホウ素中性子捕捉療法用中性子照射装置 ホウ素中性子捕捉療法用治療計画プログラム
販売名	【BNCT治療システムNeuCure™（ニューキュア）】 医療機器製造販売承認番号　：30200BZX00084000　令和2年3月11日付 【BNCT線量計算プログラムNeuCure™ドーズエンジン】 医療機器製造販売承認番号　：30200BZX00083000　令和2年3月11日付
区分	C2（新技術）
使用医薬品	一般名：ボロファラン(10B) 販売名：ステボロニン点滴静注バッグ9000mg/300ml
保険点数	238,500点(総額として全ての項目に適合した場合)
診療報酬点数区分	M001-4（1のイ、注2、注3），M001（3の注3）をそれぞれ準用
適応疾患	切除不能な局所進行または局所再発の頭頸部癌
保険適用日	2020年6月1日

Clinical indications and curative effects

- At present, the indications approved for marketing treatment are patients with locally advanced or recurrent head and neck cancer which cannot be surgically removed.
- Since 2001, nearly 2,000 cases have been completed in the world, including phase 1 and 2 clinical trials of head and neck tumors, glioma, melanoma and liver cancer.
- **Up to now, almost of 500 patients have been treated in Japan . （after approved）**
- **The treatment has a significant therapeutic effect, high safety, and no major adverse reactions.**

Cases of BNCT treatment as of 2020

Common head and neck tumors: **thyroid cancer, nasopharyngeal carcinoma, laryngeal cancer, nasal sinus cancer, parotid gland cancer, tongue cancer, gingival cancer, secondary malignant tumors of the neck, etc.**

TABLE 1 Boron neutron capture therapy in cancer treatment

Type of cancer	Number of patients	Country	Year	Reference
Recurrent				[7]
Recurrent multifo				[20]
Head and				[8]
	gland carcinomas, and 3 sarcomas)			
Recurrent malignant meningioma	19	Japan	2005-2011	[121]
Recurrent malignant meningioma	30	Finland	2003-2010	[122]
Recurrent late stage head and neck cancer	10	China	2003-2004	[123]
Recurrent head and neck malignancies	6	Japan	2004	[124]
Recurrent malignant gliomas	7	Japan	2013-2014	[125]
Glioblastoma	21	Japan	2002-2007	[126]
Glioblastoma multiforme	9	Czech Republic	2000-2002	[127]
Glioblastoma multiforme	53	USA	1994-1999	[28]
Brain tumors	22	USA	1996-1999	[128]
Glioblastoma multiforme	6	USA	2002-2003	[129]
Extensive squamous cell carcinoma	1	Japan	2007	[130]
Glioblastoma multiforme	17	Sweden	2002	[131]
Recurrent hepatic cancer	1	Japan	2011	[132]
Recurrent lung cancer	1	Japan	2012	[133]
Recurrent laryngeal cancer	9	Finland	2006-2012	[112]
Extramammary Paget's disease	2	Japan	2012	[134]
Vulvar melanoma and genital extramammary Paget's disease	7	Japan	2005-2014	[93]

BNCT Clinical Effect (Phase Two Data)

BNCT shows high efficacy in head and neck cancer patients with no other treatment options



Response Evaluation	Effective Quantity （%） (n=21)
CR *2	5 (23.8)
PR	10 (47.6)
SD	5 (23.8)
PD	0 (0.0)
NE	1 (4.8)
Response *1 (CR + PR) （%）	**71.4**

K. Hirose et.al., Radiotherapy and Oncology 155 (2021) 182–187

*1 Response: After cancer patients receive cancer treatment, the tumor shrinks by more than 30% or disappears, and lasts for at least 4 weeks

*2 Complete Response: the tumor disappears completely and lasts for at least 4 weeks

Progress of clinical trials for each indication

Tumor Type	Indication	Preclinical	Phase I	Phase II	Phase III	Approval
Head & Neck	Locally advanced or locally recurrent unresectable head and neck tumors	Phase II（July 2016- May 2018）*Phase III not required		Obtained regulatory approval（March 2020）		Marketing（May 2020）
Glioma	Recurrent malignant glioma	Phase II（February 2016- June 2019）				* Application submitted to PMDA
Meningioma	Recurrent malignant meningioma	Clinical Trial Application（July 2019）		Phase II in progress		*Investigator-initiated trial, following-up

Clinical efficacy of indications for glioma that have been submitted to PMDA for marketing

中國生物科技服務

- In May 2021, a study report of 24 patients with recurrent malignant glioma treated by BNCT showed that the median survival time of malignant glioma with high RPA increased from 4.4 months to 18.9 months after BNCT treatment. The one-year survival rate increased from 4-5% to 79%.
- No serious adverse reactions were observed.
- The indication has completed the clinical phase II trial and is expected to be approved for marketing in 2023.



Neuro-Oncology Advances
3(1), 1–9, 2021 | doi:10.1093/noajnl/vdab067 | Advance Access date 20 May 2021

1

Accelerator-based BNCT for patients with recurrent glioblastoma: a multicenter phase II study

Glioma

Shinji Kawabata, Minoru Suzuki, Katsumi Hirose, Hiroki Tanaka, Takahiro Kato, Hiromi Goto, Yoshitaka Narita, and Shin-Ichi Miyatake

Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan (S.K., S.I.-M.); Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori, Osaka, Japan (M.S., H.T.); Southern Tohoku BNCT Research Center, Koriyama, Fukushima, Japan (K.H.; T.K.); Department of Neurosurgery, Southern Tohoku Research Institute for Neuroscience, Koriyama, Fukushima, Japan (H.G.); Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan (Y.N.)

Corresponding Author: Shin-Ichi Miyatake, MD, PhD, Department of Neurosurgery, Osaka Medical and Pharmaceutical University, 2–7 Daigaku-machi, Takatsuki City, Osaka 569-8686, Japan; Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, 2–7 Daigaku-machi, Takatsuki City, Osaka 569-8686, Japan (current) (shinichi.miyatake@ompu.ac.jp).

Abstract

Background. Boron neutron capture therapy (BNCT) utilizes tumor-selective particle radiation. This study aimed to assess the safety and efficacy of accelerator-based BNCT (AB-BNCT) using a cyclotron-based neutron generator (BNCT-30) and ^{10}B-boronophenylalanine (SPM-011) in patients with recurrent malignant glioma (MG) (primarily



Project progress

2020H1	2020H2	2021H1	2021H2	2022H1	2022H2	2023H1	2023H2	2024H1	2024H2

In March 2020, BNCT was approved for marketing in Japan.

Incorporated into Japanese national health insurance in June 2020

In October 2020, CBSH signed a framework agreement with Japan.

In November 2021, officially passed the access evaluation of Hainan Boao Lecheng International Medical Tourism Pilot Zone.

On 28 February 2022, the first zone admission agreement was formally signed, and the preparatory work began.

The auction was completed on 27 May 2022.

On 25 September 2022, the foundation stone was laid.

In January 2023, the Practicing License for Medical Institution was granted.

Hospital construction and equipment installation are expected to be completed by the end of 2023.

Hospital is expected to be put into operation in 2024 to treat patients.

Media editorial

中国生物科技服务引进日本先进癌症治疗技术 国内首个“硼中子俘获疗法”商业应用落地

2022-06-24 09:19:16　　浏览量：101.8万

来源：经济参考网

经济参考报　　查看详情 〉

香港上市公司中国生物科技服务（8037.hk）（中生科服）引进日本最先进癌症治疗技术硼中子俘获疗法（BNCT）治疗设备及服务签约仪式6月23日在日本举行，这是继癌症传统治疗手段“外科手术、放射疗法和化学药物疗法”后国际先进的治疗技术。依据该技术手段创建的鹏博海南硼中子癌症治疗中心，将于今年8月在海南博鳌乐成国际医疗旅游先行区开工建设，预计2024年接待患者。BNCT项目的引进，不仅

the Xinhua News Agency: CBSH introduces Japan's advanced cancer treatment technology and the first commercial application of "boron neutron capture therapy" in China has landed


異例の聞き取り
粒子線治療世界へ
「原発60年超」了承
日本経済新聞
2月14日
火曜日
トルコ・シリア 死者3.5万人
地震1週間 建設業者らに逮捕状
資産額など数値基準
投資家保護 仕組み債制限
高リスク・説明不足でトラブル
日証協
蒸気のことなら
TLV
フィリピン大統領インタビュー
台湾有事「巻き込まれる」

2023.2 Nikon Keizai Shimbun

Japanese BNCT system has been confirmed to be introduced into China


日本経済新聞　2023年(令和5年)2月
進化するがん治療 1
日本発・粒子線 世界へ

Sumitomo Heavy Industries & STELLA PHARMA

STELLA PHARMA,

Founded on June 1, 2007, the company is headquartered on the 8th floor of ORIX Koryobashi Building, No. 7, 3 Bum 2, Chuo-ku, Osaka City, Osaka Prefecture. The main business scope is the development, manufacture and marketing of boron drugs necessary for use in BNCT (boron neutron capture therapy). In 2015, it launched the world's first boron drug that can be used for BNCT, and was listed on the Tokyo Stock Exchange in April 2021. It is the pioneer of BNCT boron drug research and development in the world and the only boron drug manufacturer approved for listing in the world.

STELLA PHARMA 住友重机械

- Sumitomo Heavy Machinery Industry Co., LTD. (hereinafter referred to as "Sumitomo"), a subsidiary of Sumitomo Group, was founded on November 1, 1934, with its headquarters located at No. 1-1-1-2-butum-mu Osaki, Shinagawa Ward, Tokyo, Japan. As of March 31, 2022, the registered capital is 30,871.65 million yen, the total number of employees is 24,584 people, and the total annual profit of the 2021 fiscal year is 943,979 million yen. We have branches all over the world. Its product line spans multiple fields, and its cyclotron is the world's only approved medical device for BNCT.

Exclusive Right

- 2022/6， CBSH (8037.hk) signed cooperation agreements with Sumitomo Heavy Industries LTD., the world's only approved device manufacturer, and Stella Pharma. Obtained the exclusive agency rights in Greater China (excluding Taiwan).

Development Plans

Step 01	Step 02	Step 03	Step 04
Construction	**Registration**	**Multi-Centres**	**Development**
Boao BNCT Centre	Upon operation of the Hainan Center, will jointly establish BNCT Research Institute with Huashan Hospital and apply to the NMPA for domestic registration and marketing	Establish centres in multiple regional central cities in China (in the form of franchising and outsource management)	Develop new tumor indications

Will then be:

- Hainan's first BNCT center to treat patients;
- The **second country** in the world to provide BNCT treatment;
- Able to offer advanced tumor treatment services to patients in China, Southeast Asia and even the world.

Business model

1. Cooperate with Japan	General agent of Greater China
2. Patient sources/Partners	Signed cooperation institutions include: Shanghai Huashan Hospital, Peking University Shenzhen Hospital,Ping An Health, Foshan Chancheng Hospital, China General, CUHK, etc
3. business model	Asset-light model: self-built Hainan Center +BNCT multi-center operation management; And product sales; Profit point: direct + join hospital management, regional agent authorization, equipment sales, drug supply, consumables supply, maintenance, center construction design, agent construction, equipment installation and commissioning, professional training, etc
4. Additional indication	At present, the indications in Japan are skin cancer, liver cancer, breast cancer, melanoma, brain tumor, liver tumor, bladder cancer, local recurrent breast cancer, lung cancer, colon cancer, malignant mesothelioma, angiosarcoma,

Huashan Hospital, Ping An Health MOU announcement

2023.5.2MOU with CUHK

Commercial prospect

item	Conventional radiation therapy	Proton radiation	Heavy ion radiation therapy	BNCT
Equipment costs	10 to 30 million	500 million	1 billion	About 300 million
Facility size	small	big	Max	Middle
Cost of treatment time	About 30 times	About 30 times	About 15 times	1 or 2 times
Number of treatments/units/year	~1600	~1600	~1400	>2500
Patient cost (ten thousand yuan)	2~15	30	≥30	45 ~ 60

According to the data in the "National Health Education Reader on Prevention of Major Diseases" released by the Chinese Association of Actuaries at the end of December 2020, the average treatment cost of cancer in China is between 220,000 and 800,000 yuan, ranking at the forefront of the treatment cost of major diseases.

BNCT Project Team

Professional Operations Team

Prof. Wang Enmin

Ph.D, Chief Physician, Doctoral Supervisor

Director of Cyberknife Treatment Center of Huashan Hospital affiliated to Fudan University, the first doctor of gamma knife in China, and one of the pioneers of radiation neurosurgery.

Member of International Stereotactic Radiosurgery Association, International Cyberknife Association, American Radiotherapy Association (ASTRO), Standing Committee of Neuroradiology Group Expert Committee of China Association of Neurosurgeons, Standing Committee of Precision Radiotherapy Technology Branch of China Biomedical Engineering Society, Standing Committee of Skull Base Surgery Branch of China Medical and Health Care International Exchange Promotion Association, and Member of Chinese Medical Association.

Liu Junyang

Associate Researcher, M.D, Ph.D

Southern Medical University, Bachelor of Medical Imaging

National Niigata University, Japan, Ph.D. in molecular cell medicine and tumor radiotherapy.

Postdoctoral workstation of China People's Liberation Army Air Force General Hospital, postdoctoral fellow in tumor radiotherapy.

Member of Beijing Society of Precision Radiology, member of Japan Society of Radiation Oncology (JASTRO)

He worked in the radiotherapy department of the affiliated tumor hospital of Harbin Medical University and the radiotherapy department of the general hospital of China PLA Air Force.

Prof. Chen Xianzhao

Chief Physician

Director and chief expert of radiotherapy department of Hainan Cancer Hospital

He has served as an external professor of Hainan Medical College, an expert in the expert database of Hainan Provincial Health Bureau, director of radiotherapy department of Hainan Provincial People's Hospital for 12 years, and director of Cyberknife Center of 187 Hospital of People's Liberation Army for 4 years.

Academic status: He served as the 3rd, 4th, 5th and 6th member of Radiation Oncology Branch of Chinese Medical Association. Chairman of the 1st, 2nd and 3rd sessions of Hainan Radiation Oncology Committee. Editors of the 4th, 5th and 6th Chinese Journal of Radiation Oncology.

Prof. Duan Yuan

Director of Gamma Knife Center, Hainan Provincial People's Hospital

Academic status: Member of Standing Committee of Neurosurgery Committee of Hainan Medical Association, Member of Radiosurgery Committee of World Chinese Neurosurgery, and Member of Glioma Committee of Chinese Medical Association.

Advisory Expert Team

Prof. Yang Jun, Changjiang Scholar, Doctor, Doctoral Supervisor.

- Visiting Professor of Huashan Hospital affiliated to Fudan University; Changjiang scholars; Doctor of Biomedical Engineering, Medical Image Processing and Medical Physics, University of Miami, USA
- Member of North American Radiosurgery Standards Setting, Executive Director of American Radiosurgery Association, Executive Director of Global Cyberknife Users Association, and Chairman of American Radiosurgery Physicist Committee.

In 2006, he participated in the establishment of the famous CyberKnife Center in Philadelphia, USA.
From 2013 to 2019, he served as the chief physicist of Delaware County Hospital and Alliance Oncology (the third largest professional radiotherapy and the largest chain of precision radiotherapy in North America), responsible for and managing the technical, clinical and scientific research work of Alliance Oncology in 34 radiotherapy centers in the United States.

Prof. Xie Fang, Doctor, Chief Physician, Graduate Tutor

The earliest pharmaceutical expert engaged in research of radiopharmaceuticals and boron drugs in China.
Associate Research Fellow, PET Center, Huashan Hospital, Fudan University. The key laboratory of radiopharmaceuticals, Ministry of Education, Beijing Normal University, and Rosendorf Research Center (Helmholtz-Zentrum Dresden-Rossendorf, HZDR) jointly trained doctors. Postdoctoral fellow at UT Southwestern Medical Center at Dallas (UTSW). Engaged in imaging diagnosis of neurodegenerative diseases for more than ten years. Presided over many scientific research projects such as the National Natural Science Foundation of China.

Prof. Wang Yang, Doctor, Chief Physician, Graduate Tutor
Chief Physician, CyberKnife Center, East Hospital of Huashan Hospital, Fudan University

In 2003, he studied in the Department of Radiotherapy, B.I.D Hospital, Harvard Medical School, USA. In 2006, he won the first prize for scientific and technological progress of the Ministry of Education. In 2007, he participated in American CyberKnife Training. In 2016, he won the first prize of Shanghai Science and Technology Progress Award. In 2017, he became a tutor of master's degree in oncology at Fudan University. In 2009, he won "Excellent Huashan People" and "Excellent party member of Huashan Hospital" in 2017.

Professor Sheng Xiaofang, Ph.D., Chief Physician, Graduate Tutor
Director of Radiotherapy Center, Jing 'an Branch, Huashan Hospital, Fudan University

Mainly engaged in radiotherapy, chemotherapy and supportive treatment of nervous system tumors. Participated in the compilation of several guidelines and textbooks, such as China Glioma Diagnosis and Treatment Guide, China Multidisciplinary Glioma Diagnosis and Treatment (MDT) Expert Consensus, China Glioma Radiotherapy Expert Consensus, NCCN Neurological Tumor Treatment Guide (Chinese version), Practical Surgery, Modern Oncology, Neuronavigation Surgery, China Central Nervous System Glioma Immune and Targeted Therapy Expert Consensus.

Market demand of indications

Head and neck cancer is the seventh most common cancer in the world. The 5-year survival rate of metastatic stage IV head and neck cancer is less than 4%.

The number of new cases and deaths in China in 2020: **220,000 thyroid cancers and about 10,000 deaths; 62,000 people with nasopharyngeal carcinoma, 40,000 deaths, 30,000 oral cancers (including lip cancers), 29,000 laryngeal cancers, 142,000 other head and neck cancers and 75,000 deaths; (Data source WHO2021 Global Cancer Report)**

- **There are about 90,000 new cases of glioma and 50,000 deaths in China every year.**

- The 5-year survival rate of malignant glioma is less than 5%.
- Glioma ranks second in the incidence of childhood tumors, second only to leukemia, so it is very suitable for BNCT treatment.
- High incidence among those 40-55 years old. In the past 30 years, the incidence rate has increased and become younger.

High recurrence rate and high mortality rate.

Source: Diagnostic and therapeutic criteria for glioma /2018 edition.

- In China, there are more than 8,000 new cases of malignant melanoma every year,
- The 5-year survival rate of melanoma patients is only 65%.

- Melanoma has become the fastest growing tumor in all malignant tumors in recent years.
- In 2012, there were 232,000 new cases of melanoma and 55,000 deaths worldwide.

Market demand of BNCT

- According to the plan of the Ministry of Health and Welfare of Japan, Japan plans to equip every million people with 0.5 sets of BNCT equipment, with a total demand of about 70 sets;
- **Corresponding to the population base of China and the needs of patients, the demand for equipment should be no less than 700 sets. By then, every big city needs a BNCT treatment center.**
- Articles from the American Society of Radiotherapy Oncology show that:

We estimate the opportunity for BNCT is **$30 billion** per annum globally for both the neutron system and the target drugs.

“十四五”大型医用设备配置规划(单位:台)				
细分品类	“十四五”末规划总数	相比“十三五”末增幅	其中:“十四五”规划数	相比“十三五”增幅
重离子质子放射治疗系统	60	216%	41	156%
高端放射治疗类设备	125	155%	76	-60%
PET/MR	210	204%	141	83%
PET/CT	1667	107%	860	56%
腹腔内窥镜手术系统	819	215%	559	148%
常规放射治疗类设备	5333	58%	1968	20%
伽马射线立体定向放射治疗系统	327	41%	95	-49%

(数据来源:卫健委、国信证券)

- 2023.7 The National Health Commission issued the notice of the "14th Five-Year Plan" Large-scale Medical Equipment Configuration Plan, clarifying the number of large-scale medical equipment planned configuration and access standards during the "14th Five-Year Plan" period. According to this plan, during the "14th Five-Year Plan" period, the country plans to configure 3,645 large medical equipment, of which: 117 in class A and 3,528 in Class B. According to the analysis of a number of securities institutions, the configuration plan is expected to promote the expansion of the high-end medical equipment market. At the same time, stimulate the procurement demand of medical institutions, especially middle and grassroots medical institutions, and related equipment companies are expected to usher in accelerated performance.

The data and information on this page are from Cyber Med and American Society of Radiotherapy and Oncology.

Highlights

BNCT

CAR-T

Precision Diagnostics

Corporate

Outlook

Cell therapy：Independent innovation of immune cell therapy technology

中國生物科技服務

Shanghai Longyao – The first echelon of immune cell drug research and development enterprise worldwide. Has two technology platforms with independent patents.

国家药品监督管理局

药物临床试验批准通知书

受理号：CXSL2000315　　通知书编号：2021LP00063

上海隆耀生物科技有限公司：

根据《中华人民共和国药品管理法》及有关规定，经审查，2020 年 11 月 04 日受理的 LY007 细胞注射液符合药品注册的有关要求，同意开展复发/难治性 CD20 阳性 B 细胞非霍奇金淋巴瘤（B-NHL），包括弥漫大 B 细胞淋巴瘤（DLBCL）和转化型滤泡性淋巴瘤（TFL）的临床试验。

- On 20 January 2021, IND application was officially approved by China CDE;
- The **first and currently the only** CD20-targeted CAR-T product declared and approved for IND in China;
- With 10 authorized patents and 21 pending patents, the scope of protection covers China, Hong Kong, Macau, the United States, Europe, Japan, South Korea and other countries and regions.

Two Technology Platforms

- OX40 Costimulatory Signaling Platform
- Universal CAR-T Technology Platform

CAR-T-OX40 is expected to be a rising star in the treatment of solid tumors

In December, 2021, the team of Professor Carl June from the University of Pennsylvania found that T Cell failure could be reversed by inhibiting ID3 or SOX4, which is expected to make CAR-T cells fight solid tumors more efficiently. The related results were published in Cell, which coincided with the idea of Longyao CAR-T-OX40 platform.

Besides reversing T-cell depletion, Longyao's CAR-T-OX40 platform can also enhance the killing of CAR-T cells, reduce their apoptosis, promote their expansion and promote their secretion of more effective factors. It has more comprehensive functions and is more helpful for CAR-T to overcome solid tumors.

The “Father of CAR-T”
Prof. Carl H.June

Important academic achievements

Professor Fu Yangxin
MD, PhD
Chief Scientific Advisor

Prof. of SW Medical Center, UTexas

Chair Prof. of School of Medicine, UChicago

Physician, Affiliated Hospital of UChicago

200+ SCI Papers

40,000+ Academic citations

Fields of study focus on MOA of LIGHT and other TNF superfamily members in the tumor immunology

Professor Yang Xuanming
PhD
Chief Scientist of Longyao

Special Researcher, School of Life Science and Technology, SJTU

Post-doc, Department of Pathology, UChicago

Prof., The Recruitment Program of Young Professionals

Fields of study focus on immunosuppression in TME, CAR-T and T cell adoptive cancer therapy

CAR-T-OX40：highlights

Important Academic Achievements： By CSO Dr. Yang Xuanming. About CD20-CART-OX40 official publication at 《 Science Translational Medicine 》on JAN, 17th, 2021

Science Translational Medicine Contents News Careers Journals

Read our COVID-19 research and news.

SHARE RESEARCH ARTICLE CANCER

A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity

Huihui Zhang[1,2,3*], Fanlin Li[1,2,3*], Jiang Cao[4*], Xin Wang[5], Hai Cheng[4], Kunming Qi[4], Gang Wang[5], Kailin Xu[4], Junnian Zheng[6], Yang-Xin Fu[7] and Xuanming Yang[1,2,3†]

[1]Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.
[2]Joint International Research Laboratory of Metabolic and Developmental Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.
[3]Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, China.

Science Translational Medicine
Vol 13, Issue 578
27 January 2021
Table of Contents

ARTICLE TOOLS
Email
Print
Download Powerpoint
Request Permissions
Citation tools

ED FOLDERS
e to my folders

A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity

Huihui Zhang[1,2,3*], Fanlin Li[1,2,3*], Jiang Cao[4*], Xin Wang[5], Hai Cheng[4], Kunming Qi[4], Gang Wang[6], Kailin Xu[4], Junnian Zheng[6], Yang-Xin Fu[7], Xuanming Yang[1,2,3†]

Although chimeric antigen receptor (CAR)–modified T cells have shown great success in the treatment of B cell malignancies, this approach has limited efficacy in patients with solid tumors. Various modifications in CAR structure have been explored to improve this efficacy, including the incorporation of two costimulatory domains. Because costi
engineered a
antigen to rec
most effective
capability com
up-regulation
of the NF-κB (r
to the kinase AKT) pathways. OX40 signaling not only enhanced the cytotoxicity of CAR-T cells but also reduced exhaustion markers, thereby maintaining their function in immunosuppressive tumor microenvironments. In mouse tumor models and in patients with metastatic lymphoma, these CAR-T cells exhibited robust amplification and antitumor activity. Our findings provide an alternative option for CAR-T optimization with the potential to overcome the challenge of treating solid tumors.

In this article, the research team found that the addition of OX40 co-stimulatory factors provides a possible solution to the problem of **CAR-T treatment of solid tumors.**

发 明 专 利 证 书

局长
申长雨

PCT patent granted in China, US, Europe, Japan and Korea

国家药品监督管理局

药物临床试验批准通知书

受理号：CXSL2000315　　通知书编号：2021LP00063

上海隆耀生物科技有限公司：

根据《中华人民共和国药品管理法》及有关规定，经审查，2020 年 11 月 04 日受理的 LY007 细胞注射液符合药品注册的有关要求，同意开展复发/难治性 CD20 阳性 B 细胞非霍奇金淋巴瘤（B-NHL），包括弥漫大 B 细胞淋巴瘤（DLBCL）和转化型滤泡性淋巴瘤（TFL）的临床试验。

LY007 and LY011:Excellent clinical efficacy, 100% ORR in lymphoma

Research findings and IPs



International first-class and experienced clinical PI team

Academician Saijuan Chen
Director of National Translational Medical Research Centre (Shanghai)

Fellow of Chinese Academy of Engineering

Foreign Member of Académienationale de médecine de France

PhD Sc, Paris Diderot University

Vice President of China Association for Science and Technology

Director of Shanghai Institute of Hematology

Professor Weili Zhao
Deputy Director & Chief Physician of Ruijin Hospital, SH

Winner of the National Science Fund for Distinguished Young Scholars

PhD, Paris Diderot University

Vice Chair of the Lymphoma Alliance of CSCO

Led a number of programs of National High-Tech R&D Program (863 Program), National Natural Science Foundation and Provincial Level R&D Projects

上海交通大學 SHANGHAI JIAO TONG UNIVERSITY

上海交通大学医学院附属瑞金医院

International first-class and experienced clinical PI team

Prof. Jianyong Li
MD, PhD
Chief Physician
Dept. of HematAology Jiangsu People's Hospital

Postdoc, Hosp. Ctr, University of Nantes

Deputy Chairperson, Integrative Hematology Professional Committee, CMDA

Led more than 30 major national research projects
Published 600+ Papers

Acted as Investigator in certain CAR-T clinical trials for companies such as Legend Biotech.

Prof. Junnian Zheng
MD, PhD
Chancellor of Xuzhou Medical University

Investigator initiating Longyao's solid tumor IIT project

Director of Cancer Biotherapy Institute of Jiangsu
Leading Medical Talent of Jiangsu

Registered to initiate international clinical trials for 11 CAR-T therapies in NIH, domestic clinical trials in China for 24 CAR-T therapies, completed more than 300 cases humanized CAR-T immune cell treatment of blood tumors.

江苏省人民医院 JIANGSU PROVINCE HOSPITAL 江苏省红十字医院

南京医科大学 NANJING MEDICAL UNIVERSITY

江苏省肿瘤生物治疗研究所

Roadmap of Longyao：
International Leading Immunocyte Therapy Company



Clear Development Path of Longyao



Rich Pipeline of Innovative CAR-T Products

	Target	Scope of Rights	Pre-clinical	Pre-IND	Phase I	Patent
CD20 CAR-T-OX40	CD20				r/r B cell lymphoma or leukemia 2022.10 complete d reinfusion for 3 patents	
CLDN18.2 CAR-T-OX40	CLDN18.2				Solid Tumors (Pancreatic/gastric cancer)	申請中
CD19 UCAR-T	CD19				r/r B cell lymphoma or leukemia	
	CD20 CAR-T-OX40 Global FTO review has been completed					
CD20 UCAR-T	CD20				r/r B cell lymphoma/leukemia	
DC1-CTL	NA				Solid Tumors	
HPV TCR-T	NA				Solid Tumors	
EBV TCR-T	NA				Solid Tumors	

Effector Cell | Activating Cell | Regulatory Cell | PCT or Chinese Patent has been filed

- Longyao is working on multiple pipelines. Currently, **CLDN18.2-CART-OX40** and **CD19 UCAR-T** are undergoing investigator initiated clinical trials. IND applications will be filed for these 2 products once applicable.

Excellent Therapeutic Efficacy of CD20 CAR-T-OX40

CD20 CAR-T-OX40 Lower T-Cell Exhaustion Molecule



CD20 CAR-T-OX40 Stronger Lethality



CD20 CAR-T-OX40 Lower Apopotosis



CD20 CAR-T-OX40 Longer Vitro Expansion



CD20 CAR-T-OX40 More Effector Molecule



CAR-T-OX40: A Promising Solution for Solid Tumors

✓ CAR-T-OX40 exhibited excellent anti-tumor activities in Lymphoma/Metastatic Lymphoma Model and Subcutaneous Solid Tumor Model

Subcutaneous Solid Tumor Model







Lymphoma/Metastatic Lymphoma Model





CD20 CAR-T-OX40 has Demonstrated Excellent Clinical Efficacy

- ✓ 5 relapsed/refractory B cell lymphoma patients have been treated with CD20 CAR-T-OX40
- ✓ 100% ORR, 2 CR, 3 PR
- ✓ No serious CAR-T-related neurotoxicity; No serious CRS
- ✓ Dosage low to 5X10^5 cell/kg，far lower than similar product 10^6-10^{8}cell/kg
- ✓ Two weeks after IND approved the CAR-T cells can reach 80% -90% of T cells，far higher than similar product
- ✓ CAR-T cells can also be detected after 100 days，about 2% of T-cells，validated the anti-exhaustion advantages of the OX40

Longitudinal Scan



Before treatment



After treatment

Transverse Scan



Before treatment



After treatment

Financial Performance

Highlights

BNCT

CAR-T

Precision Diagnostics

Corporate

Outlook

Precision Diagnostics Team： Professional Background, International Perspective

Anthony Wu
Chairman of the board of directors of Sunrise Diagnostic Centre
10 years as Chairman of the Hong Kong Hospital Authority

Standing member of Chinese People's Political Consultative Conference
Public Policy Expert of the National Health and Family Planning Commission
Chief advisor of the National Administration of Traditional Chinese Medicine,

Dr. Ning Li
Director of Sunrise Diagnostic Centre
Many years experience in molecular diagnosis

PhD of Bioinformatics at Chinese Academy of Sciences
Vice President at BGI
Expert in EU Commission for Innovation &Research

Dr. Christina TO Kar Wing
Sunrise Diagnostic Centre Lab Director

Registered Medical Laboratory Technologist in HK
PhD in Pathology at University of Hong Kong
Former Research Assistant at University of Hong Kong
Former Laboratory Supervisor at Hong Kong Polytechnic University

KK Chan
Hong Kong - Class I Registered Medical Laboratory Technician

MBA(HSM), MIBMS, AFCHSE, ACHSM (Australia),
Registered Part1 (HKMLTB)
He used to be the chief chemist of the pathology Department of the hospital
He was the department manager of Pathology Department of Eastern Hospital

Dr. Gang Song
Founder/CEO of Pillar Biosciences
Postdoc at Harvard Univ.
Program leader & Scientist at IQuum

Jeffrey Lai, Ph.D. NRCC,MB,MLT I
AMDL Lab Director
5+ years of CAP certification and director experience

Dr. Ken Kwok, Ph.D., MPhil,

AMDL R&D Director
15+ years of molecular diagnostics experience

Daniel Lau
PHC Lab Director
MLT I

Bachelor of Biological Sciences, Edinburgh Napier University
MSc in Biomedicine, Edinburgh Napier University

Precision Diagnostics Highlights

中國生物科技服務

Three Medical Labs

Multiple Certifications

- ✓ CAP
- ✓ HOKLAS
- ✓ NATA/RCPA
- ✓ ISO 15189
- ✓ ISO 13485
- ✓ China, US & EU Approved NGS

Broad Scope of Services

- ✓ Pathology, blood, biochemistry
- ✓ Imaging
- ✓ PCR
- ✓ NGS
- ✓ ….

History

- ✓ Victory Medical Lab was set up in 1949;
- ✓ PHC Centra Lab was set up in 1968; being one of the few most time-honored ICLs in Hong Kong

Sunrise Diagnostic Centre Limited 華昇診斷中心

AMDL Asia Molecular Diagnostics Laboratory Limited 亞洲分子診斷實驗室有限公司

標準病理檢驗所有限公司 PHC Medical Diagnostic Centre Ltd. Pathology & HealthCare

Sunrise – One of the largest and fastest COVID-19 testing service providers in Hong Kong

- The largest contractor of the first universal testing in HK;
- One of the largest COVID-19 testing lab in HK;
- Completed a total of 20 million test samples (31 December 2022);
- Up to 130,000 single tube test samples per day;
- Took the lead in launching rapid testing and settled in Hong Kong airport and ports;

Post-Pandemic Era Growth Drivers:

Signed service agreements with 9 district health centres covering 4 million+ people and has launched:

- Diabetes adiponectin detection
- HPV self-sampling;
- cPass™ neutralizing antibodies;
- COLOTECT (non-invasive high-sensitivity detection of colorectal cancer and its precancerous lesions) etc

Sunrise Diagnostic Centre Limited 華昇診斷中心

AMDL - Genetic testing technology from Harvard University

- Jointly established HKSP laboratory with Pillar Biosciences;
- Possess the **world's first NGS multi-cancer companion diagnostic (CDx diagnostic test for lung and colon cancer) reagent with complete certificates in China, the United States and Europe**, and exclusive commercialization rights in many countries and regions in Asia;
- **The only institution in Hong Kong** that can perform cancer companion testing locally;
- Tumor NGS testing services have been provided for Sanatorium Hospital, Gleneagles Hospital, Queen Mary Hospital, Chinese University Medical Center, ICON Cancer Center, HEAL Cancer Center, etc.

FDA NMPA CE



瑪麗醫院 QUEEN MARY HOSPITAL

養和 H.K.S.&H.

Gleneagles HONG KONG 港怡醫院

ICON CANCER CENTRE ICON 癌症中心

HEAL NF HEALTH

香港中文大學醫院 CUHK Medical Centre

Pillar Biosciences is a clinical cancer diagnostics company based in Boston, USA and Shanghai, China.

PILLAR BIOSCIENCES

Dana-Farber Cancer Institute

illumina®

Dartmouth-Hitchcock NORRIS COTTON CANCER CENTER

COLUMBIA | COLUMBIA UNIVERSITY IRVING MEDICAL CENTER

- **PHC Medical Diagnostic Center has a history of 55 years, est. since 1968. It has high brand awareness and is one of the largest third-party medical testing centers in HK.**
- **The general medical examination items covered are comprehensive: Pathology, blood biochemistry** radiology, biological immunology, microbiology and cell analysis, specialties, etc.
- Launched the neutralizing antibody test corresponding to Omicron, which was **approved by WHO, FDA and EUA**;
- **180,000 samples** are processed per year on average. **2.38 million customers** are accumulated.
- CRO detection business has been carried out in cooperation with pharmaceutical companies such as **AstraZeneca – AZ, GlaxoSmithKline – GSK, Merck – MSD**, etc.
- Managed by a professional MLT team of registered chemists, pathologists, radiologists, and chemists to ensure accurate and effective reports.

MSD gsk AstraZeneca

market share :

International pharmaceutical factory	20	clinic	9,470
commercial insurance institution	71	Corporate client	1,134
medical group	763	private client	2,380,000

High-quality chain one-stop health management center

- **Precision Health Care Services was set up in 1994, controlled by Henglong Family funds;**
- **3 health management centers in Hong Kong, located in Causeway Bay, Jordan and Tsuen Wan;**

Services Included:

- Medical examination
- Vaccination
- Doctor consultation
- Customized medical examination service
- Nucleic acid sampling
- Government-designated cooperative clinic
- Door-to-door services
- One-stop Health Management Center

Customer groups come from enterprises and insurance customers:

Enterprise Honor

2020

Gelonghui
Anti-epidemic Outstanding Contribution Award

2021

Sunrise - HKB Technology Excellence Awards

2022

AMDL - Top Clinical Laboratory Services Company in Asia Pacific by Life Sciences Review

2022

Sunrise - Hong Kong's Most Outstanding Business Awards

Highlights

BNCT

CAR-T

Precision Diagnostics

Corporate

Outlook

Strong Collaboration Network

Research Institutions

NIBS 北京生命科学研究所 National Institute of Biological Sciences, Beijing

中国疾病预防控制中心 CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION

香港中文大學 The Chinese University of Hong Kong

南京医科大学 Nanjing Medical University

徐州醫科大学 XUZHOU MEDICAL UNIVERSITY

澳門科技大學 MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY

Hospitals

上海交通大学医学院附属瑞金医院

复旦大学 · 中国红十字会 華山醫院

江苏省人民医院 JIANGSU PROVINCE HOSPITAL 南京医科大学第一附属医院 THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY
江苏省红十字医院 THE RED CROSS HOSPITAL OF JIANGSU 江苏省临床医学研究院 JIANGSU CLINICAL MEDICINE RESEARCH INSTITUTION

北京大学深圳医院 PEKING UNIVERSITY SHENZHEN HOSPITAL

徐州醫科大学附属醫院 THE AFFILIATED HOSPITAL OF XUZHOU MEDICAL UNIVERSITY

佛山禅醫 Foshan Fosun Chancheng Hospital 佛山复星禅诚医院

Corporate Organizations

STELLA PHARMA 住友重机械

PILLAR BIOSCIENCES DaAnGene 华大基因 BGI

CSPC 石药集团 通用技术 GENERTEC 好技术·好生活 Regi-Trans

金斯瑞生物科技 Make Research Easy 药明康德 WuXi AppTec OBiO 和元生物

GE Healthcare 未名集团 SINOBIOWAY 昭衍 JOINN

阿里健康 力高健康生活 REDCO HEALTHY LIVING

平安好医生 美团 中国太平 CHINA TAIPING

Market Capitalization：Undervalued, Huge Room For Growth





Note：Data as of 09/08/2023

5-Years Roadmap
Successfully built an integrated platform for diagnosis and treatment

中國生物科技服務

- In November, changed its name to CBSH.
- The HK Biotechnology Board 18A was announced in Decen

- Was included in MSCI HK Micro-Cap Index in May.
- Completed the acquisition of Shanghai Longyao Biotechnology CAR-T project in

- Established the HKSP lab with Pillar Bio. Asia's first cancer companion diagnostic center launched.

- Established Sunrise
- 1.68 million people were tested for the first time.
- Performance increased by 11 times, and revenue exceeded 600 million.

- CART-OX40 IND was approved by CDE
- The IVD of lung cancer and colon cancer of Pillar/AMDL was approved by FDA.

- BNCT officially entered the zone agreement, and signed a purchase agreement with SHI and SP.
- CAR-T products have been reinfused in 3 cases in Shanghai Ruijin Hospital
- Pillar/AMDL's IVD of lung cancer and colon cancer was approved by China, America and Europe.
- Sunrise testing has exceeded 20 million test samples (data as of 31 December 2022)



Highlights

BNCT

CAR-T

Precision Diagnostics

Corporate

Outlook

Development prospects in the next three years

中國生物科技服務控股
China Biotech Services

Precision Diagnostics

- Committed to becoming the largest third-party laboratory with business coverage at home and abroad;
- Committed to becoming an advanced IVD enterprise covering R&D, production and sales of upstream reagents and equipment, and downstream testing services;
- Continue to contribute cash flow and profits to support the overall development of listed companies in the next three years, and meet the financial indicator requirements for listing on the main board.

BNCT

- Hainan Centre will be put into operation in 2024;
- Committed to becoming a multi-center cancer diagnosis and treatment institution covering Greater China;
- Strive to complete the multi-center construction layout within 3-5 years

CAR-T

- Strive for the first drug to enter the second phase of clinical trials as soon as possible, and achieve patent licensing cooperation to generate income

Q & A